Skip to content
Screener

Savara SVRA Shares (Diluted)

Shares (Diluted) at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
73.4M-13.1%
XER
Xeris Biopharma Holdings, Inc.XERS
172.8M+8.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
61.3M+8.9%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
54.6M+1.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
21.9M+7.9%
PVL
Palvella TherapeuticsPVLA
13.1M+18.8%

Other financials

Income statement

See full
Revenue-
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%
EPS (diluted)-$0.16-14.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.17B+152%
Enterprise value$1.16B+143%

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Savara’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Net loss per share:
Basic and diluted$(0.16)$(0.14)$(0.31)$(0.26)
Weighted-average common shares outstanding:
Basic and diluted253,569,891216,431,348253,426,018216,289,923
Other comprehensive income (loss):
Gain (loss) on foreign currency translation(71)502(166)774
Unrealized loss on short-term investments(34)(86)(281)(240)
Total comprehensive loss$(40,333)$(29,985)$(77,959)$(56,506)

Cover / Front Matter

FAQ

What is Savara's shares (diluted)?
Savara (SVRA) reported shares (diluted) of 253.6M in Q2 2026.
How has Savara's shares (diluted) changed year-over-year?
Savara's shares (diluted) increased by 17.2% year-over-year, from 216.4M to 253.6M.
What is the long-term trend for Savara's shares (diluted)?
Over 4 years (2021 to 2025), Savara's shares (diluted) has grown at a 14.0% compound annual growth rate (CAGR), from 516M to 871.4M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Savara's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude